Epitra 100mg Syrup contains Levetiracetam, an antiepileptic agent used for the treatment of partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures in patients with epilepsy. Levetiracetam acts by modulating synaptic neurotransmitter release through binding to the synaptic vesicle protein SV2A, thereby reducing neuronal excitability and seizure propagation. Epitra 100mg Syrup offers a convenient oral liquid formulation suitable for pediatric and adult patients who have difficulty swallowing tablets. The syrup is typically administered twice daily, with dosage individualized based on patient age, weight, renal function, and clinical response. Common adverse effects may include dizziness, somnolence, headache, and fatigue, while serious side effects are rare but can include behavioral changes or hypersensitivity reactions. Caution is advised in patients with renal impairment, and dose adjustments may be necessary. Epitra should be used under strict medical supervision, with regular monitoring to assess efficacy and tolerability. It is important to adhere to prescribed dosing schedules and not to discontinue therapy abruptly to avoid seizure exacerbation. Epitra 100mg Syrup is a valuable therapeutic option in the comprehensive management of epilepsy, improving seizure control and patient quality of life.